COMMITMENTS AND CONTINGENT LIABILITIES - Additional (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
Jun. 30, 2022	Dec. 31, 2021
Commitments And Contingencies Line Items
Bank guarantee	$ 567	$ 618
Royalty rate	7.00%	7.00%
Advance payments on account of car leases	$ 57
Advance payments for facilities rental	$ 150
Net sales of Company products sold by Company's licensees
Commitments And Contingencies Line Items
Royalty payment as a percentage of grants	0.65%	0.65%
MOROCCO
Commitments And Contingencies Line Items
Bank guarantee	$ 225
Israeli Innovation Authority (IIA)
Commitments And Contingencies Line Items
Grant income	4,085	$ 4,065
Royalty expense	0	0
Liabilities assumed	$ 5,159	$ 5,061
Israeli Innovation Authority (IIA) \| Future sales of developed product
Commitments And Contingencies Line Items
Royalty payment as a percentage of grants	100.00%	100.00%
Israeli Innovation Authority (IIA) \| Minimum \| Future sales of developed product
Commitments And Contingencies Line Items
Royalty rate	3.00%	3.00%
Israeli Innovation Authority (IIA) \| Maximum \| Future sales of developed product
Commitments And Contingencies Line Items
Royalty rate	3.50%	3.50%
Althera
Commitments And Contingencies Line Items
Liabilities assumed	$ 474	$ 474
Potential payment	$ 1,500	$ 1,500
Althera \| Future gross revenues derived from purchased intellectual property
Commitments And Contingencies Line Items
Royalty rate	2.00%	2.00%
Ramot \| Net sales of all of the Company's products
Commitments And Contingencies Line Items
Royalty rate	2.50%	2.50%
HekaBio K.K.
Commitments And Contingencies Line Items
Milestone number of ordinary stock options	271,588	271,588
Stock option exercise price	4.42%	4.42%
HekaBio K.K. \| Reimbursement Price
Commitments And Contingencies Line Items
Royalty rate	3.50%	3.50%
HekaBio K.K. \| Revenue from distribution receipts
Commitments And Contingencies Line Items
Royalty rate	10.00%	10.00%
BGN Technologies
Commitments And Contingencies Line Items
Royalty rate	3.00%
BGN Technologies \| Net sales of Company products sold by Company's licensees
Commitments And Contingencies Line Items
Grant income	$ 10,000
Royalty rate	2.00%
BGN Technologies \| Sales of alpha radiation products
Commitments And Contingencies Line Items
Royalty rate		0.75%
BGN Technologies \| Sales of product containing intellectual property
Commitments And Contingencies Line Items
Royalty rate	1.50%	1.50%
BGN Technologies \| License revenue related to jointly developed intellectual property
Commitments And Contingencies Line Items
Royalty rate	4.00%	4.00%
BGN Technologies \| License revenue related to intellectual property
Commitments And Contingencies Line Items
Royalty rate	8.00%	8.00%
Royalty payment as a percentage of grants	8.00%
BGN Technologies \| Minimum \| Sales of alpha radiation products
Commitments And Contingencies Line Items
Royalty rate	1.50%
BGN Technologies \| Maximum \| Sales of alpha radiation products
Commitments And Contingencies Line Items
Royalty rate	0.75%
Cambridge University Hospitals NHS Trust \| Revenue generated from patent
Commitments And Contingencies Line Items
Royalty rate	5.00%	5.00%
Cambridge University Hospitals NHS Trust \| Net sales of treatment for Squamous Cell Carcinoma
Commitments And Contingencies Line Items
Royalty rate	2.00%	2.00%

Carrying amount of accumulated prepayments received by financial institutions from borrowers for car leases.

No definition available.

Name:	drts_AdvancePaymentsByBorrowersForCarLeases
Namespace Prefix:	drts_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Carrying amount of accumulated prepayments received by financial institutions from borrowers for facilities rental.

+ References

No definition available.

+ Details

Name:	drts_AdvancePaymentsByBorrowersForFacilitiesRental
Namespace Prefix:	drts_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	drts_CommitmentsAndContingenciesLineItems
Namespace Prefix:	drts_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Income earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose.

+ References

No definition available.

+ Details

Name:	drts_GrantIncome
Namespace Prefix:	drts_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The number of shares purchasable through stock options dependent on the achievement of various milestones.

+ References

No definition available.

+ Details

Name:	drts_MilestoneNumberOfOrdinaryStockOptions
Namespace Prefix:	drts_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

The maximum potential amount of payment based on a agreement.

+ References

No definition available.

+ Details

Name:	drts_PotentialPayment
Namespace Prefix:	drts_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The percentage at which royalty payments will be paid out on relative to the amount of grants received plus interest at LIBOR rate.

+ References

No definition available.

+ Details

Name:	drts_RoyaltyPaymentAsPercentageOfGrants
Namespace Prefix:	drts_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage at which royalty payments will be paid out on.

+ References

No definition available.

+ Details

Name:	drts_RoyaltyRate
Namespace Prefix:	drts_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The per share exercise price of option.

+ References

No definition available.

+ Details

Name:	drts_StockOptionExercisePrice
Namespace Prefix:	drts_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The fair value of liabilities assumed in noncash investing or financing activities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586

+ Details

Name:	us-gaap_LiabilitiesAssumed1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.16)
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

+ Details

Name:	us-gaap_ShortTermBankLoansAndNotesPayable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	drts_MethodOfPaymentRoyaltiesAxis=drts_NetSalesOfAllCompanySProductSoldByCompanySLicensesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=country_MA
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=drts_IsraeliInnovationAuthorityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	drts_MethodOfPaymentRoyaltiesAxis=drts_FutureSalesOfDevelopedProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=drts_AltheraMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	drts_MethodOfPaymentRoyaltiesAxis=drts_FutureGrossRevenuesDerivedFromPurchasedIntellectualPropertyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=drts_RamotMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	drts_MethodOfPaymentRoyaltiesAxis=drts_NetSalesOfAllCompanySProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=drts_HekaBioKKMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	drts_MethodOfPaymentRoyaltiesAxis=drts_ReimbursementPriceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	drts_MethodOfPaymentRoyaltiesAxis=drts_DistributionReceiptsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=drts_BgnTechnologiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	drts_MethodOfPaymentRoyaltiesAxis=drts_SalesOfAlphaRadiationProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	drts_MethodOfPaymentRoyaltiesAxis=drts_SalesOfProductContainingIntellectualPropertyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	drts_MethodOfPaymentRoyaltiesAxis=drts_LicenseRevenueToJointlyDevelopedIntellectualPropertyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	drts_MethodOfPaymentRoyaltiesAxis=drts_LicenseRevenueRelatedToIntellectualPropertyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=drts_CambridgeUniversityHospitalsNhsTrustMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	drts_MethodOfPaymentRoyaltiesAxis=drts_RevenueGeneratedFromPatentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	drts_MethodOfPaymentRoyaltiesAxis=drts_NetSalesSquamousCellCarcinomaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: